Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Making Investors Richer.
Moderna extended its winning streak to a fifth consecutive day on Wednesday, climbing 11.55 percent to end at $61.80 apiece, as investors loaded their portfolios ahead of its Investor Day.
In a notice, Moderna Inc. (NASDAQ:MRNA) said that it will host an Investor Event at 9 AM ET next Thursday, June 25.
Photo from Unsplash
The company said that it is set to discuss and feature research and early development programs, highlighting how its mRNA platform, together with advances in AI and robotics, is accelerating innovation and creating opportunities to expand into new therapeutic areas.
In other news, Moderna Inc. (NASDAQ:MRNA) on Tuesday said that it is anticipating the launch of three vaccines for flu plus COVID, seasonal flu, and norovirus over the next two years.
At the same time, it is expecting important clinical milestones this year, including potential pivotal data readouts for its investigational individualized neoantigen therapy (Intismeran autogene) and a therapeutic for the rare genetic disease propionic acidemia, which could support the possible launch of its first oncology and rare disease products.
In other news, Moderna Inc. (NASDAQ:MRNA) appointed Ester Banque as its new chief commercial officer, effective on Monday, June 15. She is tasked to focus on continuing to build out the company’s global commercial organization, leading execution across product launches, and expanding presence in new markets.
While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.